ArticleAnalytical chemistry2026
Sensitive Detection of Epidermal Growth Factor in Lung Cancer Patients by Electrochemical Biosensors.
Article in Analytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the most common cancer worldwide, responsible for more deaths per year than any other cancer, with non-small cell lung cancer (NSCLC) being the most prevalent form. Elevated epidermal growth factor (EGF) levels have been associated with NSCLC and decreased survival, highlighting its potential as a prognostic and predictive biomarker. This study proposes developing and validating a novel impedimetric electrochemical biosensor for the sensitive and accurate detection of EGF in serum samples from patients with lung adenocarcinoma. The biosensor was constructed by electropolymerization of polypyrrole nanotubes (PPy-NTs) on screen-printed carbon electrodes, followed by the deposition of carboxylated multiwalled carbon nanotubes (MWCNT-COOH) used for the immobilization of biorecognition elements. Anti-EGF antibodies were covalently immobilized on the MWCNT-COOH-modified surface, and bovine serum albumin (BSA) was used to block nonspecific interactions. Electrochemical impedance spectroscopy (EIS) was employed to characterize each fabrication step and to detect EGF. The biosensor demonstrated a wide linear detection range from 500 fg mL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.